Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are collecting detailed information about patients with venous thromboembolism VTE to improve understanding of this condition, especially in groups often excluded from clinical trials such as pregnant women, elderly patients, and those with severe health issues. This observational registry aims to provide data that can help reduce death rates, recurrences of blood clots, bleeding problems, and arterial events related to VTE. This study gathers clinical details about each patient, including other health conditions, and tracks the type, dose, duration, and results of antithrombotic treatments over the first three months. The registry is accessible online to assist doctors in managing complex cases by comparing patient profiles and identifying those at higher risk of complications. Participants clinical status and treatment outcomes are recorded, focusing on recurrence of VTE, bleeding events, and mortality over a three-year period. The information supports the creation of predictive scores to help healthcare providers identify patients at higher risk. The study started in 2001 and plans to continue until 2027, with ongoing data collection and follow-up.
Actively Recruiting
Researchers are evaluating whether letrozole is more effective than standard chemotherapy for treating patients with hormone receptor positive low-grade serous epithelial ovarian carcinoma LGSCO. This phase III, open-label, randomized trial aims to see if letrozole can extend progression-free survival compared to carboplatin and paclitaxel chemotherapy. The study also explores tumor response, quality of life, pain, overall survival, safety, and genetic markers related to the disease. Participants will be randomly assigned to one of two groups one group takes letrozole tablets daily by mouth for up to 60 months or until disease progression, while the other group receives carboplatin and paclitaxel intravenously on day 1 every 21 days for 6 to 8 cycles. The treatments are compared directly to assess their effects on cancer control and patient well-being. During the study, participants will have regular assessments including tumor response evaluations, quality of life questionnaires, pain inventory, and safety monitoring according to standard criteria. Genetic profiling and circulating tumor DNA will be analyzed to understand disease characteristics. Progression-free survival will be tracked for up to 84 months, with ongoing monitoring of overall survival and adverse events. Participants will be followed closely to observe treatment effects and side effects throughout the trial period.
Actively Recruiting
Researchers are evaluating the impact of a healthy lifestyle implemented Survivorship Care Plan LS-SCP on the quality of life in long-term lymphoma survivors who have been in remission for at least 3 years and up to 10 years. This is a prospective, randomized, open-label, multicenter study involving two groups to compare the effects of the lifestyle plan versus standard follow-up care. Participants in the experimental group will follow a Survivorship Care Plan that includes nutritional guidance and physical activity recommendations for 6 months. Compliance with this plan will be monitored through automatic bi-monthly phone calls. The control group will receive no specific intervention and will continue with usual clinical follow-up, completing questionnaires at 6 and 12 months after randomization. During the study, all participants will complete validated questionnaires assessing quality of life, fatigue, anxiety, depression, and other health aspects at baseline, 6 months, and 12 months. Clinical assessments and evaluations of metabolic and cardiovascular outcomes, cognitive function, and adherence to healthy lifestyles will also be conducted. The main outcome measured is the global quality of life over a period of up to 30 months from the study start.
Actively Recruiting
Tuberculosis TB is increasingly affecting children and young people, not just the elderly, especially in industrialized countries. Factors such as immigration from high TB areas, HIV-induced immunodeficiency, immunosuppressive drugs, and resistant TB strains contribute to its rise. The available data on TB in children is scarce due to diagnostic challenges and poor integration with national surveillance systems, suggesting the disease may be underreported both in Italy and worldwide. This observational study follows pediatric patients from 0 to 18 years old who have active or latent TB or have been exposed without infection. The study collects information on these patients over an average treatment period of 6 months and evaluates outcomes at 24 months, focusing on the epidemiology of TB in this age group. The research aims to improve understanding of TB transmission and progression in children. Participants undergo regular clinical observations and assessments according to World Health Organization criteria, with data collected from initial observation through treatment completion and follow-up. The study monitors disease progression, infection status, and outcomes, helping identify latent TB cases and supporting better surveillance. Total participation varies but includes baseline and long-term follow-up over 24 months.
Actively Recruiting
This research aims to assess the early safety and effectiveness of a procedure called percutaneous deep foot venous arterialization in patients with chronic limb-threatening ischemia CLTI who have no other revascularization options. CLTI is the most advanced stage of lower limb arterial disease, carrying high risks of death and major amputation. About 5-10% of patients with peripheral arterial disease develop CLTI, which has a 20% mortality rate within six months of diagnosis. For some patients, standard revascularization methods are not possible or effective, and this study explores an alternative approach to restore blood flow. The study is a multicenter, prospective, single-arm observational study including patients undergoing the PiPER procedure, which involves using veins to reroute arterial blood flow to the foot instead of damaged arteries. The procedure will follow current clinical practice without extra tests or procedures. Patients will be monitored through clinic visits at 30 days, 6 months, 12 months, and 24 months after the procedure to track their progress. Participants will be involved in scheduled follow-up visits where researchers will collect data on their demographics, medical history, treatment details, and health outcomes for up to two years. Assessments will include safety outcomes at 30 days and 6 months, procedural success, blood vessel openness, amputation rates, wound size, oxygen levels in tissues, and disease severity classifications at several intervals. This long-term monitoring aims to evaluate the procedures safety and effectiveness in this high-risk patient group.
Actively Recruiting
Healthy Volunteer
Reference intervals are important tools used to interpret laboratory test results. This research aims to evaluate indirect methods for determining these reference intervals using routine clinical laboratory data instead of relying on samples from actively recruited healthy individuals. The study focuses on improving accuracy and efficiency in defining reference intervals, particularly for complete blood count CBC parameters, and highlights the need for age-specific reference intervals due to variations in hemoglobin levels among the elderly. The study is observational and analyzes large-scale retrospective data collected from routine clinical laboratory tests across multiple Italian regions. It evaluates the RefineR statistical method, an open-source tool designed to distinguish normal from pathological data efficiently. The study will assess regional differences, establish age- and sex-specific reference intervals, and evaluate variations caused by different laboratory instruments over a period of up to three years. Participants are not actively recruited since the study uses existing laboratory data. Researchers will analyze these data to define reference intervals and compare results across regions, age groups, and testing platforms. The primary outcome is the definition of indirect reference intervals for CBC parameters. Secondary outcomes include assessments of regional and instrument variations. The study will run from October 2025 to June 2028, with no direct participant involvement beyond data analysis.